US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Neuroscience and Healthcare ETF

31.39

-0.4722-1.48%

Volume:321

Turnover:10.16K

Market Cap:6.28M

PE:- -

High:31.72

Open:31.72

Low:31.39

Close:31.87

52wk High:43.01

52wk Low:27.40

Shares:200.00K

Float Shares:200.00K

Volume Ratio:0.15

T/O Rate:0.16%

Dividend:0.32

Dividend Rate:1.01%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Praxis Precision Med Price Target Maintained with a $582.00/Share by Needham

Dongxing Medical Ventures into Neural Interface with 20 Million Yuan as A-Share Drug Makers Flock to New Frontier

Alkermes ADHD Data Boosts Confidence in ALKS7290, Orexin Pipeline, RBC Says

MT Newswires Live

Analysts’ Opinions Are Mixed on These Healthcare Stocks: AnaptysBio (ANAB), Alkermes (ALKS) and Iradimed (IRMD)

Alkermes Plc : Jefferies Raises Target Price to $83 from $78

THOMSON REUTERS

Xenon Pharmaceuticals Presents at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit Fireside Chat

Alkermes data show measurable improvements in ADHD, says H.C. Wainwright

Scholar Rock Grants Inducement Equity Awards Covering 83,102 Shares to New Hires

Scholar Rock Reports New Employee Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS

Alkermes Price Target Maintained with a $62.00/Share by Needham

Alkermes Plc : Baird Raises Target Price to $61 from $58

THOMSON REUTERS

Alkermes Says ADHD Drug Candidate Showed Meaningful Improvements in Phase 1b Study; Shares Up Pre-Bell

MT Newswires Live

U.S. Stocks on the MOVE-Accenture, Arhaus, Alkermes

Alkermes jumps 8% to $46.99 after Phase I adult ADHD data

Alkermes Shares Rise 6.5% Premarket After Positive Results from Early-Stage Study of Adhd Drug

THOMSON REUTERS

Alkermes announces Phase 1b results of ALKS 7290 in ADHD

Alkermes Reports Positive Phase 1b Proof-of-Concept Data for ALKS 7290 in Adult ADHD

Alkermes -Alks 7290 Generally Well Tolerated at All Doses in Healthy Volunteers and Adults with Adhd

THOMSON REUTERS

Alkermes Announces Positive Phase 1B Results Demonstrating Clinical Proof-of-Concept for Alks 7290 in Adults with Attention-Deficit Hyperactivity Disorder (Adhd)

THOMSON REUTERS

Alkermes - Phase 2 Study of Alks 7290 in Adults with Adhd Enrolling, Data Expected in 2027

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/IBRN/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IBRN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","market":"US","secType":"STK","nameCN":"iShares Neuroscience and Healthcare ETF","latestPrice":31.3928,"timestamp":1791489600000,"preClose":31.865,"halted":0,"volume":321,"delay":0,"changeRate":-0.014818766671896981,"floatShares":200000,"shares":200000,"eps":0,"marketStatus":"Pre-Mkt","change":-0.4722,"latestTime":"10-09 08:34:33 EDT","open":31.72,"high":31.72,"low":31.3928,"amount":10162,"amplitude":0.010268,"askPrice":50.22,"askSize":200,"bidPrice":30.03,"bidSize":4,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1791552600000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":31.3928,"sharesOutstanding":150000,"nav":31.865918,"aum":6373183.6,"dividendRate":0.010149,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":31.72,"preClose":31.3928,"latestTime":"16:10 EDT","volume":6,"amount":188.2912,"timestamp":1791490204224,"change":0.3272,"changeRate":0.010423,"amplitude":0},"volumeRatio":0.14874885048069997,"impliedVol":0.0879,"impliedVolPercentile":0.528},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","floatShares":200000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.14874885048069997,"shares":200000,"dividePrice":0.3186,"high":31.72,"amplitude":0.010268,"preClose":31.865,"low":31.3928,"week52Low":27.4025,"pbRate":"--","week52High":43.01,"institutionHeld":0,"latestPrice":31.3928,"committee":-0.960784,"eps":0,"divideRate":0.010149,"volume":321,"delay":0,"ttmEps":0,"open":31.72,"prevYearClose":32.3193,"prevWeekClose":32.552,"prevMonthClose":33.265,"prevQuarterClose":33.265,"fiveDayClose":32.8651,"twentyDayClose":37.33,"sixtyDayClose":38.0334},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBRN\",params:#limit:5,,,undefined,":[{"date":"2025-12-16","symbol":"IBRN","amount":0.319807,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2024-12-17","symbol":"IBRN","amount":0.10114,"announcedDate":"2024-12-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2023-12-20","symbol":"IBRN","amount":0.006303,"announcedDate":"2023-12-19","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"},{"date":"2023-06-07","symbol":"IBRN","amount":0.008241,"announcedDate":"2023-05-12","type":"dividend","market":"US","newRecordDate":"2023-06-08","defaultRemindTime":1686144600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-06-13","payableDate":"2023-06-08","currency":"USD","dateTimestamp":1686110400000,"payDate":"2023-06-13"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBRN\",market:\"US\",,,undefined,":[{"executeDate":"2023-06-07","recordDate":"2023-06-08","paymentDate":"2023-06-13","value":0.008241,"currency":"USD"},{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.006303,"currency":"USD"},{"executeDate":"2024-12-17","recordDate":"2024-12-17","paymentDate":"2024-12-20","value":0.10114,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-19","value":0.319807,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBRN\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBRN\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669469243","title":"Praxis Precision Med Price Target Maintained with a $582.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2669469243","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669469243?lang=en_us&edition=fundamental","pubTime":"2026-09-24 17:55","pubTimestamp":1790243700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PRAX/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","LU0320765992.SGD","IE0002141913.USD","IE0009355771.USD","IE00BFTCPJ56.SGD","LU0889565916.HKD","IE00BJT1NW94.SGD","BK4139","IE00B2B36J28.USD","IE00B4R5TH58.HKD","IBRN","LU0109394709.USD","PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136670948","title":"Dongxing Medical Ventures into Neural Interface with 20 Million Yuan as A-Share Drug Makers Flock to New Frontier","url":"https://stock-news.laohu8.com/highlight/detail?id=1136670948","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136670948?lang=en_us&edition=fundamental","pubTime":"2026-09-23 22:13","pubTimestamp":1790172814,"startTime":"0","endTime":"0","summary":"Jiangsu Canopus Wisdom Medical Technology Co.,Ltd. (Dongxing Medical) is diving into the booming brain-computer interface sector with a modest trial investment. On the evening of September 22, the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","301290","07233","02846","BK0251","BK1147","82846","83130","83188","02827","159982","03188","03130","399300","MNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669232251","title":"Alkermes ADHD Data Boosts Confidence in ALKS7290, Orexin Pipeline, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2669232251","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669232251?lang=en_us&edition=fundamental","pubTime":"2026-09-22 23:39","pubTimestamp":1790091552,"startTime":"0","endTime":"0","summary":"Alkermes (ALKS) recent attention-deficit/hyperactivity disorder data increased its management's confidence in ALKS7290 and reinforced the potential of its broader \"orexin pipeline,\" RBC Capital Market","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MEDX","ALKS","PSIL","PSCH","IBRN","BK4139","FBT","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669678146","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: AnaptysBio (ANAB), Alkermes (ALKS) and Iradimed (IRMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669678146","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669678146?lang=en_us&edition=fundamental","pubTime":"2026-09-22 18:50","pubTimestamp":1790074221,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on AnaptysBio (ANAB), Alkermes (ALKS) and Iradimed (IRMD). AnaptysBi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-anaptysbio-anab-alkermes-alks-and-iradimed-irmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-anaptysbio-anab-alkermes-alks-and-iradimed-irmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALKS","FBT","BK4585","XBI","BK4581","FFTY","LABU","ANAB","BK4588","IBRN","XLV","BK4082","LU0128526141.USD","PSCH","IRMD","LU0029874061.USD","PSIL","HCSG","BK4137","MEDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669611593","title":"Alkermes Plc : Jefferies Raises Target Price to $83 from $78","url":"https://stock-news.laohu8.com/highlight/detail?id=2669611593","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669611593?lang=en_us&edition=fundamental","pubTime":"2026-09-22 13:28","pubTimestamp":1790054919,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nFWN45E03X:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MEDX","ALKS","FBT","IBRN","BK4139","PSCH","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669198606","title":"Xenon Pharmaceuticals Presents at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2669198606","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669198606?lang=en_us&edition=fundamental","pubTime":"2026-09-22 04:01","pubTimestamp":1790020877,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals presents at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit fireside chatXenon Pharmaceuticals will present at the TD Cowen Novel Mechanisms in Neuropsychiatry & E","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nNDLbHYW3r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","LU2095319765.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","SG9999014021.USD","XENE","LU2210149790.SGD","SBIO","SG9999014013.SGD","LU0314104364.USD","BK4112","IE00BN0W2V16.EUR","NDAQ","BK4588","SG9999014005.SGD","IE00BQXX3D17.EUR","IBRN","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","LU2210150020.SGD","BK4585","IE00BN0W2W23.USD","IE00BQXX3C00.GBP","BK4139","IE00BQXX3F31.USD","IE00B64PRP62.GBP","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669167844","title":"Alkermes data show measurable improvements in ADHD, says H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2669167844","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669167844?lang=en_us&edition=fundamental","pubTime":"2026-09-22 00:40","pubTimestamp":1790008814,"startTime":"0","endTime":"0","summary":"H.C. Wainwright keeps a Neutral rating on Alkermes (ALKS) after the company reported the first clinical evidence of an orexin-2 receptor agonist pr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alkermes-data-show-measurable-improvements-in-adhd-says-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alkermes-data-show-measurable-improvements-in-adhd-says-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FBT","ABVC","IBRN","ALKS","PSCH","MEDX","PSIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669616216","title":"Scholar Rock Grants Inducement Equity Awards Covering 83,102 Shares to New Hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2669616216","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669616216?lang=en_us&edition=fundamental","pubTime":"2026-09-22 00:27","pubTimestamp":1790008046,"startTime":"0","endTime":"0","summary":"Scholar Rock grants inducement equity awards covering 83,102 shares to new hiresScholar Rock granted inducement equity awards covering 83,102 shares to 10 newly hired employees under its 2022 Induceme","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nNDL5QkCsN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","BK4139","THNR","SRRK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669164272","title":"Scholar Rock Reports New Employee Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669164272","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669164272?lang=en_us&edition=fundamental","pubTime":"2026-09-22 00:00","pubTimestamp":1790006400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nTUA74KV9J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","THNR","SRRK","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669916926","title":"Alkermes Price Target Maintained with a $62.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2669916926","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669916926?lang=en_us&edition=fundamental","pubTime":"2026-09-21 22:11","pubTimestamp":1789999860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALKS/analyst-ratings","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRN","PSIL","ALKS","MEDX","PSCH","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669166716","title":"Alkermes Plc : Baird Raises Target Price to $61 from $58","url":"https://stock-news.laohu8.com/highlight/detail?id=2669166716","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669166716?lang=en_us&edition=fundamental","pubTime":"2026-09-21 21:33","pubTimestamp":1789997614,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nFWN45D0EZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MEDX","PSIL","IBRN","FBT","BK4139","ALKS","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669976165","title":"Alkermes Says ADHD Drug Candidate Showed Meaningful Improvements in Phase 1b Study; Shares Up Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2669976165","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669976165?lang=en_us&edition=fundamental","pubTime":"2026-09-21 20:43","pubTimestamp":1789994623,"startTime":"0","endTime":"0","summary":"Alkermes  said Monday its drug candidate ALKS 7290 showed clinically meaningful improvements from baseline on exploratory endpoints in a phase 1b study in patients with attention-deficit hyperactivity disorder or ADHD.The company said it measured improvements using the Adult ADHD Investigator Symptom Rating Scale and Clinical Global Impression-Severity Scale after 14 days of treatment.ALKS 7290 was generally well-tolerated at all doses tested in healthy volunteers and adults with ADHD, the company said. The study enrolled 50 adults with ADHD in a double-blind, placebo-controlled, parallel-group trial with two cohorts, it added.The company said it enrolled the first of an expected 312 participants in a phase-2 study this month. The trial will evaluate the safety and efficacy of once-daily and split doses of ALKS 7290 compared to placebo, with data expected next year.Shares of the company were up over 7% in Monday's premarket activity.Price: 46.50, Change: +3.11, Percent Change: +7.17","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MEDX","ALKS","PSIL","PSCH","IBRN","BK4139","FBT","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669099168","title":"U.S. Stocks on the MOVE-Accenture, Arhaus, Alkermes","url":"https://stock-news.laohu8.com/highlight/detail?id=2669099168","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669099168?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:52","pubTimestamp":1789991524,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Accenture, Arhaus, AlkermesSeptember 21 (Reuters)-Wall Street futures advanced on Monday, led by AI stocks, as a 2% slide in oil prices pulled Treasury yields lower on sig","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nL6N45D0I4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HOOZ","CONI","ROBN","LU1430594728.SGD","BK4598","LU0265550359.USD","LU2247934214.USD","BULL","LU2211815571.USD","BK4168","SG9999018857.SGD","LU0323240290.USD","PSIL","MSTY.UK","LU0289739343.SGD","REXC","ICOI","LU1116320901.HKD","CRMX","LMI3.UK","LU0868494708.USD","MSTX","LU0149725797.USD","COIG","09799","IBRN","LU0868494617.USD","HOOC","LU0477156953.USD","LU0980610538.SGD","07399","LU0157215616.USD","LU0289960550.SGD","IAI","LU0738911758.USD","BK4178","09399","BK4596","BK4134","IE00BFSS8Q28.SGD","LU1861217088.USD","07311","MSTW","LU0323239441.USD","GRML","CRML","HK0000819398.USD","HOOD","IE0004445015.USD","LU1235294995.USD","WNTR","ALKS","MSTP","PSKY","3SMI.UK","LU1894683264.USD","BK4585","BK4588","LU1228905540.USD","07711","FINX","SG9999004303.SGD","SGXZ31699556.SGD","CRPT","LU1861559042.SGD","LU1861220207.SGD","HOII","ACN","BK4539","COIX","LU1894683348.USD","BKCH","LU0081259029.USD","COIO","CRMU","BPAY","BK4595","HOOY","ARHS","BK4023","LU1366333091.USD","LU1989772840.SGD","BK4600","HODU","BK4535","IE000M9KFDE8.USD","PSCH","BK4547","BLCK","LU0648001328.SGD","COYY","LU0511384066.AUD","LU0545562505.USD","LU0661504455.SGD","MEDX","LU1883839398.USD","LU0265550946.USD","IE00BJJMRX11.SGD","IE00BJJMRY28.SGD","BITQ","LU1201861249.SGD","BK4551","MSTZ","CONL","LU1003077747.HKD","BK4566","MSDD","MSTR","07799","LU0175139822.USD","LU2596442595.SGD","SMST","COIA","LU0342679015.USD","LU1046421795.USD","SG9999018865.SGD","IE00BFSS7M15.SGD","BK4125","LU0942090050.USD","LU0545039389.USD","LU0553294199.USD","MTYY","BK4554","HOYY","09711","BK4534","BK4108","MSTY","IE00BSNM7G36.USD","BK4213","MSII","SG9999014898.SGD","3LMI.UK","MSST","LU1989772923.USD","BULG","FDIG","CONY","CUE","HOOG","LU0130102774.USD","LU1228905037.USD","LU1116320737.USD","LU2360107671.USD","IE00B7KXQ091.USD","BULU","IMST","MSTC","SG9999014914.USD","HOOX","HOOW","09311","APED","LU1585245621.USD","FIAT","MSOO","SGXZ23171101.USD","DAPP","GLND","LU0289961442.SGD","MSTU","BK4533","COII","BK4581","MSTK","LU1506573853.SGD","SG9999014906.USD","HOOI","IE00BHPRN162.USD","LU2133065610.SGD","LU0130517989.USD","LU1823568750.SGD","SG9999014880.SGD","SMI3.UK","MST","BK4561","LU1032466523.USD","BK4516","BK4127","OWNB","BK4139","LU2381873111.SGD","IBLC","LU0949170772.SGD","COIN","WBD","COIW","BK4112","FBT","SG9999017495.SGD","CONX","LU1861558580.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669163577","title":"Alkermes jumps 8% to $46.99 after Phase I adult ADHD data","url":"https://stock-news.laohu8.com/highlight/detail?id=2669163577","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669163577?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:50","pubTimestamp":1789991414,"startTime":"0","endTime":"0","summary":"07:46 EDT Alkermes (ALKS) jumps 8% to $46.99 after Phase I adult ADHD data Published first on TheFly – the ultimate source for real-time, market-mo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alkermes-jumps-8-to-46-99-after-phase-i-adult-adhd-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alkermes-jumps-8-to-46-99-after-phase-i-adult-adhd-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","ABVC","BK4139","PSIL","IBRN","ALKS","FBT","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669150485","title":"Alkermes Shares Rise 6.5% Premarket After Positive Results from Early-Stage Study of Adhd Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2669150485","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669150485?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:07","pubTimestamp":1789988867,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nFWN45A0RA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSCH","ALKS","IBRN","FBT","MEDX","PSIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669916887","title":"Alkermes announces Phase 1b results of ALKS 7290 in ADHD","url":"https://stock-news.laohu8.com/highlight/detail?id=2669916887","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669916887?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:05","pubTimestamp":1789988737,"startTime":"0","endTime":"0","summary":"Alkermes (ALKS) announced topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, the company’s novel, investigational orexin 2...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alkermes-announces-phase-1b-results-of-alks-7290-in-adhd-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alkermes-announces-phase-1b-results-of-alks-7290-in-adhd-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","BK4139","PSIL","ABVC","PSCH","IBRN","FBT","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669415062","title":"Alkermes Reports Positive Phase 1b Proof-of-Concept Data for ALKS 7290 in Adult ADHD","url":"https://stock-news.laohu8.com/highlight/detail?id=2669415062","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669415062?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:01","pubTimestamp":1789988517,"startTime":"0","endTime":"0","summary":"Alkermes reports positive Phase 1b proof-of-concept data for ALKS 7290 in adult ADHDAlkermes reported positive Phase 1b topline results for ALKS 7290 in adults with ADHD; results have already been pre","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nNDL2WW99h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBT","IBRN","ALKS","PSCH","MEDX","PSIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669505181","title":"Alkermes -Alks 7290 Generally Well Tolerated at All Doses in Healthy Volunteers and Adults with Adhd","url":"https://stock-news.laohu8.com/highlight/detail?id=2669505181","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669505181?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:00","pubTimestamp":1789988400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nTUA9RZ6JR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSIL","ALKS","IBRN","FBT","PSCH","MEDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669150548","title":"Alkermes Announces Positive Phase 1B Results Demonstrating Clinical Proof-of-Concept for Alks 7290 in Adults with Attention-Deficit Hyperactivity Disorder (Adhd)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669150548","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669150548?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:00","pubTimestamp":1789988400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nTUA9RZ6JR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSCH","PSIL","ALKS","BK4139","FBT","IBRN","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669150512","title":"Alkermes - Phase 2 Study of Alks 7290 in Adults with Adhd Enrolling, Data Expected in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2669150512","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669150512?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:00","pubTimestamp":1789988400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nTUA9RZ6JR:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALKS","PSIL","MEDX","BK4139","IBRN","FBT","PSCH"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}]}}